Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Packard, C.J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Packard, C.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Apolipoproteins: the new prognostic indicator?

C.J. Packard*

University of Glasgow, Glasgow, Scotland, U.K.

* Chris Packard, DSc, FRCPath, FRCP(Gla), Professor of Pathological Biochemistry, Glasgow Royal Infirmary, University Block, 10 Alexandra Parade, Glasgow G31 2ER, U.K.

Abstract

Accumulating evidence indicates that apolipoprotein (apo)B, apoA-I and, particularly, the apoB:apoA-I ratio are strong predictors of risk for coronary heart disease and of benefit in coronary heart disease prevention in lipid-lowering trials. For example, the Apolipoprotein related MOrtality RISk study showed that the apoB:apoA-I ratio was strongly related to increased risk for fatal myocardial infarction, and that plasma apoB and apoA-I levels and apoB:apoA-I ratio were better predictors of risk than levels of total cholesterol or triglycerides. Analysis of lipid variables in the Air Force/Texas Coronary Atherosclerosis Prevention Study population showed that baseline high-density lipoprotein cholesterol (HDL-C), apoA-I, apoB, low-density lipoprotein cholesterol (LDL-C):HDL-C ratio, total cholesterol:HDL-C ratio and apoB:apoA-I ratio significantly predicted first major acute event, whereas LDL-C and total cholesterol did not. For 1-year on-treatment values, only apoA-I, apoB and apoB:apoA-I ratio were significant predictors of a future coronary event. New statins can reduce substantially the apoB:apoA-I ratio. This is particularly evident for rosuvastatin (the latest addition to the class), which both decreases apoB and increases apoA-I. A number of conceptual and practical hurdles need to be overcome before apolipoprotein measurements can be incorporated into routine risk assessment.

Key Words: Apolipoprotein • apolipoprotein B apolipoprotein A-I ratio • coronary heart disease prevention • high-density lipoprotein cholesterol • low-density lipoprotein cholesterol • statins

References

  1. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardisation project for measurements of apolipoproteins A-I and B:III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem. 1994;39:773–781
  2. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardisation project for measurements of apolipoprotein A-I and B:IV. Comparability of apolipoprotein B value by use of international reference material. Clin Chem. 1994;40:586–592[Abstract/Free Full Text]
  3. Genest JJ, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormality in men with premature coronary heart disease. J Am Coll Cardiol. 1992;19:792–802[Abstract]
  4. Kwiterovich PO Jr., Coresh J, Smith H, et al. Comparison of the plasma levels of apolipoproteins B and AI, and other risk factors in men and women with premature coronary heart disease. Am J Cardiol. 1992;69:1015–1021[CrossRef][Web of Science][Medline]
  5. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413–419[CrossRef][Web of Science][Medline]
  6. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–1009[Abstract/Free Full Text]
  7. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation. 1996;94:273–278[Abstract/Free Full Text]
  8. Garfagnini A, Devoto G, Rosselli P, et al. Relationship between HDL-C and apolipoprotein A-I and the severity of coronary artery disease. Eur Heart J. 1995;16:465–470[Free Full Text]
  9. O'Brien T, Nguyen TT, Hallaway BJ, et al. The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. Arterioscler Thromb Vasc Biol. 1995;15:228–231[Abstract/Free Full Text]
  10. Luc G, Bard J-M, Ferrières J, et al. Value of HDL-C, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease. The PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2002;22:1155–1161[Abstract/Free Full Text]
  11. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026–2033[CrossRef][Web of Science][Medline]
  12. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108–1113[Abstract/Free Full Text]
  13. Gotto AM Jr., Whitney E, Stein EA, et al. Relation between baseline and on treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:77–84
  14. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the Long-term I tervention With Pravastatin in Ischemic Disease (LIPID) Trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation. 2002;105:1162–1169[Abstract/Free Full Text]
  15. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002;89:268–275[CrossRef][Web of Science][Medline]
  16. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk. 2001;8:383–390[CrossRef][Web of Science][Medline]
  17. Brown WV, Bays HE, Hassman DR, et alRosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J. 2002;144:1036–1043[CrossRef][Web of Science][Medline]
  18. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastation on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001;88:504–508[CrossRef][Web of Science][Medline]
  19. Wiklund O, Davidson M, Chitra R, Hutchinson H, Raza A. Rosuvastatin is more effective than atorvastatin in modifying lipid profiles and achieving National Cholesterol Education Program Adult Treatment Panel III LDL-cholesterol goals. [abstract 789]Atherosclerosis. 2002;3:237[CrossRef]
  20. Barter P, Shepherd J, Brown WV, Bays H, Southworth H, Strutt K. Rosuvastatin significantly improves lipid parameters and ability to achieve low-density lipoprotein cholesterol goals compared with pravastatin. [abstract]J Am Coll Cardiol. 2002;39(suppl B):142B
  21. Hamilton-Craig I, Schaefer E, Farnier M, et al. Rosuvastatin produces significantly greater reductions in low-density-lipoprotein cholesterol and more patients achieve treatment goals compared with simvastatin. [abstract 2811]J Am Coll Cardiol. 2002;39(suppl B):146B
  22. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003;91:33–41
  23. Hassman D, Ballantyne CM, Chitra R, Blasetto JW. Rosuvastatin lowers non-high-density lipoprotein cholesterol and apolipoprotein B values compared with atorvastatin, simvastatin, and pravastatin. Circulation. 2002;105:10 (suppl)

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Packard, C.J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Packard, C.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?